1HALO Stock Overview

A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. More details

1HALO fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	5/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 75.8% below our estimate of its fair value

Earnings are forecast to grow 14.38% per year

Earnings grew by 52.2% over the past year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Halozyme Therapeutics, Inc. Competitors

Philogen

BIT:PHIL

€878.3m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.9b

Imeik Technology DevelopmentLtd

SZSE:300896

CN¥51.9b

Neurocrine Biosciences

NasdaqGS:NBIX

US$11.8b

Price History & Performance

Summary of share price highs, lows and changes for Halozyme Therapeutics
Historical stock prices
Current Share Price	US$60.08
52 Week High	US$0
52 Week Low	US$0
Beta	1.26
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	16.61%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1HALO	IT Biotechs	IT Market
7D	12.3%	-2.1%	2.0%
1Y	n/a	1.9%	11.8%

Return vs Industry: Insufficient data to determine how 1HALO performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1HALO performed against the Italian Market.

Price Volatility

Is 1HALO's price volatile compared to industry and market?
1HALO volatility
1HALO Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.4%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.3%

Stable Share Price: 1HALO's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1HALO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1998	350	Helen Torley	halozyme.com

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product.

Halozyme Therapeutics, Inc. Fundamentals Summary

How do Halozyme Therapeutics's earnings and revenue compare to its market cap?
1HALO fundamental statistics
Market cap	€7.64b
Earnings (TTM)	€429.06m
Revenue (TTM)	€958.53m

17.8x

P/E Ratio

8.0x

P/S Ratio

Is 1HALO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1HALO income statement (TTM)
Revenue	US$1.08b
Cost of Revenue	US$258.42m
Gross Profit	US$825.88m
Other Expenses	US$340.52m
Earnings	US$485.36m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	3.94
Gross Margin	76.17%
Net Profit Margin	44.76%
Debt/Equity Ratio	312.6%

How did 1HALO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/08 14:08
End of Day Share Price	2025/05/07 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Halozyme Therapeutics, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ishan Majumdar	Baptista Research
James Birchenough	Barclays
Robert Wasserman	Benchmark Company